Metastatic Breast Cancer | Tumor

COVID-19 'Retired' Me, But Now I Can Reach For My Life Goals

January 22nd 2021, 5:00pm


With a terminal illness of metastatic breast cancer, I qualify for Social Security Disability as the COVID-19 pandemic has retired me, but that isn't stopping me from achieving my life goals.

Count Me Among The Breast Cancer Recurrence Project

January 17th 2021, 7:00pm


The Breast Cancer Recurrence Project aims to revolutionize and bring accuracy to what we know about who’s living with metastatic breast cancer.

Looking At Year 7 On This 'Cancerversary'

January 4th 2021, 5:00pm


Living beyond the statistics and finding a way to celebrate a “cancerversary” with metastatic breast cancer.

Carolina In My Mind

December 31st 2020, 5:30pm


A song can be the gateway to memories on the cancer journey.

Wigging Out Cause of Breast Cancer

December 23rd 2020, 5:00pm


Looking back at my journey with wigs, or "the girls", during my early treatment for cancer.

Being The Dog Walker With Cancer

December 18th 2020, 5:30pm


Becoming a dog owner, and the designated dog walker, while my dog and I both moved through cancer treatment is an experience that has shaped my motivation on the cancer journey.

Novel Therapy Continues to Show Prolonged, Durable Responses and Survival Outcomes in Patients with HER2-Positive Metastatic Breast Cancer

December 17th 2020, 10:00pm


Updated data from the phase 2 DESTINY-Breast01 study continues to show encouraging and durable responses for patients with HER2-positive metastatic breast cancer.

Margenza-Chemo Combo Approved by FDA for Patients with Previously Treated Metastatic HER2-Positive Breast Cancer

December 16th 2020, 9:49pm


Data from the trial that led to the Food and Drug Administration approval demonstrated that Margenza plus chemotherapy reduced the risk of disease progression or death in patients with metastatic HER2-positive breast cancer by 24%, compared with Herceptin plus chemotherapy.

Tesetaxel with Reduced Dose of Xeloda Improves Progression-Free Survival in Breast Cancer

December 12th 2020, 4:00pm


Tesetaxel, a novel agent, with Xeloda contributed to a median progression-free survival of 9.8 months, compared with 6.9 months with Xeloda alone, in patients with metastatic breast cancer.

Chemotherapy With Endocrine Therapy Shows Clinical Benefit With Improved Survival in Breast Cancer

December 12th 2020, 2:00pm


Premenopausal women with HR-positive, HER2-negative, lymph node-positive breast cancer and a risk for recurrence experienced benefits with chemotherapy plus endocrine therapy, with improvements in five-year invasive disease-free and overall survival.